Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
About Two River Group
Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products. Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
Advisory Board
Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
Dr. Paul A. Bunn, Jr.
Director of the University of Colorado Cancer Center
James Dudley endowed Chair of Cancer Research and Professor of Medicine at the University of Colorado Health Sciences Center

Paul A. Bunn, Jr., MD is Director of the University of Colorado Cancer Center in Denver, where he is the James Dudley endowed Chair of Cancer Research and Professor of Medicine at the University of Colorado Health Sciences Center. He received his medical degree from Cornell University Medical Center in New York. Dr. Bunn completed his internship and residency in medicine at University of California, H.C. Moffitt Hospital in San Francisco and his fellowship in medical oncology at the Medicine Branch of the National Cancer Institute.

Dr. Bunn previously served as chairman of the FDA's Oncology Drug Advisory Committee (ODAC) and served a term as the President of the American Society of Clinical Oncology (ASCO) and two terms on ASCO Board of Directors. He also serves on the Board of Directors of the ASCO Foundation.

Dr. Bunn is also the Executive director, former President of the International Association for the Study of Lung Cancer. He is a former President of the American Association of Cancer Institutes and chairs the Scientific Advisory Board of the Cancer League of Colorado.

Dr. Bunn is an active member of the Scientific Leadership Council in Lung Cancer. Dr. Bunn's research interests include chemotherapy in non-small cell and small cell lung cancer and he currently serves as associate editor of Lung Cancer, Annals of Surgical Oncology, Physician Data Query (PDQ) and Oncology Times. Additionally, Dr. Bunn serves on the advisory board of Clinical Cancer Research and the editorial board of Drug Resistance Updates.

Dr. Bunn's research is in the development of novel therapies for lung cancer. He has published 300 original papers with recent publications in Journal of the National Cancer Institute, Journal of clinical Oncology and Clinical Cancer Research.

Back


Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.		 Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.
© 2008 Two River Group Holdings, LLC | Terms of Use | Privacy Policy
Two River Group Holdings is a New York based venture capital firm that is focus on the formation of new companies that will acquire the rights to commerically develop pharmaceuticals, medical, therapeutics, diagnostic, and other healthcare related products.